MLYS
MLYS
US6031701013
Mineralys Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
170.604.000 192.403.000
11.3%
Operating Income -170.604.000 -192.403.000
11.3%
Pretax Income -154.651.000 -177.810.000
13.0%
Net Income Common Stockholders -154.651.000 -177.810.000
13.0%
-- --
--
-- --
--
ende